Raw red counts from a CRISPR screen for host factors required for influenza virus replication

  • Sara Clohisey Hendry (Creator)
  • Bing Shao Chia (Creator)
  • Bo Wang (Creator)
  • Ang Cui (Creator)
  • Thomas Eisenhaure (Creator)
  • Lawrence D. Schweitzer (Creator)
  • Paul Hoover (Creator)
  • Aharon Nachshon (Creator)
  • Nikki Smith (Creator)
  • Tim Regan (Creator)
  • David Farr (Creator)
  • Michael Gutmann (Creator)
  • Syed Irfan Bukhari (Creator)
  • Andy Law (Creator)
  • Maya Sangesland (Creator)
  • Irit Gat-viks (Creator)
  • Paul Digard (Creator)
  • Shobha Vasudevan (Creator)
  • Daniel Lingwood (Creator)
  • David Dockrell (Creator)
  • John G. Doench (Creator)
  • Kenneth Baillie (Creator)
  • Nir Hacohen (Creator)
  • Nicholas J Parkinson (Creator)
  • Bo Li (Creator)

Dataset

Abstract

Raw data for the CRISPR screen we conducted in collaboration with Bo Li, John Doench and Nir Hacohen can be downloaded here. Please refer to the manuscript for full details: [doi.org/10.1038/s41467-019-13965-x]

Host dependency factors that are required for influenza A virus infection may serve as therapeutic targets as the virus is less likely to bypass them under drug-mediated selection pressure. Previous attempts to identify host factors have produced largely divergent results, with few overlapping hits across different studies. Here, we perform a genome-wide CRISPR/Cas9 screen and devise a new approach, meta-analysis by information content (MAIC) to systematically combine our results with prior evidence for influenza host factors. MAIC out-performs other meta-analysis methods when using our CRISPR screen as validation data. We validate the host factors, WDR7, CCDC115 and TMEM199, demonstrating that these genes are essential for viral entry and regulation of V-type ATPase assembly. We also find that CMTR1, a human mRNA cap methyltransferase, is required for efficient viral cap snatching and regulation of a cell autonomous immune response, and provides synergistic protection with the influenza endonuclease inhibitor Xofluza.
Date made available14 Oct 2024
PublisherEdinburgh DataShare

Cite this